Could stem cells slow a fatal brain disease?

NCT ID NCT05167721

Ongoing Disease control Sponsor: Mayo Clinic Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 2 trial tests whether a patient's own stem cells, injected into the spinal fluid, can slow the progression of multiple system atrophy (MSA), a rare and fatal brain disease. The study involves 71 adults aged 30-70 with early-stage MSA. Researchers will measure changes in symptoms over time to see if the treatment is safe and effective.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: autologous mesenchymal stem cells (from the patient's own fat tissue)
What this could lead to: If it works, this could point toward a treatment that slows or stops the progression of multiple system atrophy, a currently untreatable fatal disease.
What could go wrong: This is an early Phase 2 trial with only 71 participants, so results may not apply to all patients. The treatment involves spinal injections, which carry risks like infection or nerve damage, and it may not slow the disease at all.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE SYSTEM ATROPHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

multiple system atrophy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE SYSTEM ATROPHY

Contacts and locations

Locations

Mayo Clinic

Rochester, Minnesota, 55905, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.